Literature DB >> 30705862

STAT3 cyclic oligonucleotide decoy-a new therapeutic avenue for NSCLC?

Lennard Y W Lee1, Summaya Mohammad1, Thomas Starkey1, Siow-Ming Lee2,3.   

Abstract

Entities:  

Year:  2018        PMID： 30705862      PMCID： PMC6328701          DOI： 10.21037/tlcr.2018.09.14

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  17 in total

1.  Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma.

Authors:  Richeng Jiang; Ziliang Jin; Zhujun Liu; Leina Sun; Liuchun Wang; Kai Li
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

2.  Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα- and NK cytotoxicity.

Authors:  Dorota W Kulesza; Thibault Carré; Salem Chouaib; Bozena Kaminska
Journal:  Exp Cell Res       Date:  2012-11-10       Impact factor: 3.905

3.  First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.

Authors:  Malabika Sen; Sufi M Thomas; Seungwon Kim; Joanne I Yeh; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri; Jessica Lee; Nivedita Sahu; Sonali Joyce; Maria L Freilino; Haibin Shi; Changyou Li; Danith Ly; Srinivas Rapireddy; Jonathan P Etter; Pui-Kai Li; Lin Wang; Simion Chiosea; Raja R Seethala; William E Gooding; Xiaomin Chen; Naftali Kaminski; Kusum Pandit; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancer Discov       Date:  2012-06-20       Impact factor: 39.397

4.  Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.

Authors:  Huan-Chih Chiu; Ding-Li Chou; Chin-Ting Huang; Wen-Hsing Lin; Tzu-Wen Lien; Kuei-Jung Yen; John T-A Hsu
Journal:  Biochem Pharmacol       Date:  2011-03-22       Impact factor: 5.858

5.  Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells.

Authors:  Zhen-Jie Yin; Fa-Guang Jin; Tong-Gang Liu; En-Qing Fu; Yong-Hong Xie; Rui-Lin Sun
Journal:  J Surg Res       Date:  2010-04-18       Impact factor: 2.192

Review 6.  STAT3: a target to enhance antitumor immune response.

Authors:  Heehyoung Lee; Sumanta Kumar Pal; Karen Reckamp; Robert A Figlin; Hua Yu
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 7.  STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review).

Authors:  Xiaochun Wang; Philip J Crowe; David Goldstein; Jia-Lin Yang
Journal:  Int J Oncol       Date:  2012-07-24       Impact factor: 5.650

8.  Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.

Authors:  Rui Li; Zhongliang Hu; Shi-Yong Sun; Zhuo G Chen; Taofeek K Owonikoko; Gabriel L Sica; Suresh S Ramalingam; Walter J Curran; Fadlo R Khuri; Xingming Deng
Journal:  Mol Cancer Ther       Date:  2013-07-26       Impact factor: 6.261

9.  HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer).

Authors:  L Plowright; K J Harrington; H S Pandha; R Morgan
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

10.  Comprehensive genomic characterization of squamous cell lung cancers.

Authors: 
Journal:  Nature       Date:  2012-09-09       Impact factor: 49.962
View more
  1 in total

Review 1.  Targeted protein degradation: A promise for undruggable proteins.

Authors:  Kusal T G Samarasinghe; Craig M Crews
Journal:  Cell Chem Biol       Date:  2021-05-17       Impact factor: 9.039
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.